EORTC Lung Cancer Cooperative Group Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
1998
NCT00037713
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

EORTC (Co-Sponsor Belgium)

Active Ingredients

Drugs in Phase 3 Trials (2)

bacille calmette-guerin (1 trial)

mitumomab (1 trial)

Drugs in Phase 2 Trials (1)

bortezomib (velcade) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Small Cell (Phase 3)

Lung Neoplasms (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Small Cell Lung Carcinoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3